HENGRUI PHARMA (01276.HK): two drugs get clinical trial approval
- Rekibartimab has three approved indications in China and has drawn about RMB 2.36 billion in cumulative R&D spending, unaudited.
- Adebrelimab has two approved indications and has drawn about RMB 1.37 billion in cumulative R&D spending, unaudited.
NewTimeSpace News: On 4 November 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code: 01276) published an overseas regulatory announcement under Rule 13.10B, saying units Suzhou Suncadia Biopharmaceuticals and Shanghai Suncadia Pharmaceutical received NMPA clinical trial approval notices for rekibartimab for injection and adebrelimab injection, with trials to start soon.
The application accepted on 3 August 2026 met registration requirements, clearing rekibartimab with PD-1/PD-L1 inhibitors in perioperative patients with resectable non-squamous non-small cell lung cancer and HER2 abnormalities. Rekibartimab, a self-developed HER2-targeting antibody-drug conjugate, has three approved indications in China and has drawn about RMB 2.36 billion of cumulative R&D spending; adebrelimab, a humanised anti-PD-L1 antibody, has two, with about RMB 1.37 billion invested. Both figures are unaudited.
- HENGRUI PHARMA (01276.HK): ADC filing accepted for priority review
- HENGRUI PHARMA (01276.HK): remimazolam tosilate approved for ICU mechanical ventilation sedation, R&D spend RMB222.5 million
- HENGRUI PHARMA (01276.HK): Three drugs win clinical trial approval
- HENGRUI PHARMA (01276.HK): Rezvilutamide Tablets Win Clinical Trial Approval for Prostate Cancer Phase III Study
- HENGRUI PHARMA (01276.HK): SHR-3201 wins trial approval for AD
